Drug intelligence / Profile preview

timolumab

Development stage: Phase 2
Lead developer: Biotie Therapies
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Timolumab (formerly known as BTT1023) is a fully human monoclonal antibody that targets vascular adhesion protein 1 (VAP-1), also known as amine oxidase copper-containing 3 (AOC3). By binding to VAP-1, timolumab blocks its function as an adhesion molecule, thereby reducing the entry of leukocytes into sites of tissue inflammation. This mechanism is relevant in diseases characterized by chronic inflammation and fibrosis. Timolumab has been investigated primarily for the treatment of primary sclerosing cholangitis, a progressive fibrotic liver disease with limited therapeutic options. The drug has also been studied in patients with rheumatoid arthritis and psoriasis[1][2][4][5][8].

Other names: timolumab

Targets

AOC3 (Amine oxidase copper-containing 3)

Beyond the preview

Go deeper on timolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on timolumab.